Cited by 219Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors

Urigüen, Leyre, Pérez-Rial, Sandra, Ledent, Catherine, Palomo, Tomás, Manzanares, Jorge·2004·Neuropharmacology

DOI 10.1016/j.neuropharm.2004.01.003

Open this paper in CoChat — free account

Abstract

The role of cannabinoid CB(1) receptors in the action of anxiolytics was examined. Deletion of CB(1) receptors resulted in increased anxiety-like behaviours in light/dark box, elevated plus maze and social interaction tests. Mutant mice presented basal low corticosterone concentrations and low proopiomelanocortin gene expression in the anterior lobe of the pituitary gland compared to wild-type mice. Ten minutes of restraint stress resulted in a twofold increase in corticosterone concentrations in the plasma of mutant mice, compared to wild-type mice. Bromazepam (50 or 100 microg/kg) markedly increased the time spent in light area in wild-type animals, though both doses were without effect in mutant mice. Administration of buspirone (1 or 2 mg/kg) produced anxiolytic effects in wild-type mice. In contrast, only the highest dose of buspirone had anxiolytic results in mutant mice. Our findings reveal that CB(1) receptors are involved in the regulation of emotional responses, and play a pivotal role in the action mechanism of anxiolytics. They suggest that alterations in the functional activity of the CB(1) receptor may be related to the emergence of anxiety disorders, and may affect treatment with anxiolytics.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2004.01.003

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Self-citation
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders
Heim, C., Ehlert, U., & Hellhammer, D. H. (2000) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(99)00035-9 · Cited by 1,688
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.
Young, W. S., Bonner, T. I., & Brann, M. R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9827 · Cited by 748
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martín, M., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 525
Self-citation

Show all 27 references

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 891
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis
Gobbi, G., Bambico, F. R., Mangieri, R. A., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509591102 · Cited by 692
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 698
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O. A., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 451
Neurobiology of addiction
Goodman, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 445
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 354
Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis
Hill, M. N., & Tasker, J. G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.030 · Cited by 346
Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions
Lafourcade, M., Larrieu, T., Mato, S., Duffaud, A. M., Sepers, M. D., Matias, I., Smedt, V. D., Labrousse, V. F., Brétillon, L., Matute, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2736 · Cited by 344
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288
Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans
Dlugos, A., Childs, E., Stuhr, K. L., Hillard, C. J., & de Wit, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.100 · Cited by 248
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246
Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids
Hill, M. N., & McEwen, B. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.001 · Cited by 235
Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404
Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., Rana, G. L., Russo, R., Calignano, A., Gessa, G. L., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301061 · Cited by 236
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
Gorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211
Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 196
BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice
Aso, E., Ozaita, A., Valdizán, E. M., Ledent, C. A., Pazos, Á., Maldonado, R. J., & Valverde, O. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05149.x · Cited by 189
Self-citation
Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice
Ortega-Álvaro, A., Aracil-Fernández, A., García‐Gutiérrez, M. S., Navarrete, F., & Manzanares, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.34 · Cited by 190
Self-citation
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 188
Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice
Häring, M., Marsicano, G., Lutz, B., & Monory, K. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.021 · Cited by 181
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis
Steiner, M. S., & Wotjak, C. T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00433-0 · Cited by 174
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System
McPartland, J. M., Guy, G. W., & Marzo, V. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089566 · Cited by 168
A role for cannabinoid CB1 receptors in mood and anxiety disorders
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00005 · Cited by 160
Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice
García-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
Self-citation
CB1 receptor-deficient mice as a model for depression
Valverde, O., & Torrens, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.031 · Cited by 156
The endocannabinoid system and psychiatric disorders
Parolaro, D., Realini, N., Viganò, D., Guidali, C., & Rubino, T. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.018 · Cited by 151
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice
Steiner, M. A., Marsicano, G., Nestler, E. J., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.09.008 · Cited by 146
Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
Viveros, M., Marco, E. M., Llorente, R., & López‐Gallardo, M. (2007) · Neural Plasticity · doi:10.1155/2007/52908 · Cited by 151
Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and Hippocampus
Bambico, F. R., Cassano, T., Domínguez-López, S., Katz, N., Walker, C. D., Piomelli, D., & Gobbi, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.80 · Cited by 139
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction
Lafenêtre, P., Chaouloff, F., & Marsicano, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.006 · Cited by 143
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 146
Self-citation
Role of the endocannabinoid system in depression and suicide
Vinod, K. Y., & Hungund, B. L. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.08.006 · Cited by 132
Hypothalamic-pituitary – adrenal axis-feedback control
Keller‐Wood, M. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140065 · Cited by 131
Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors
García‐Gutiérrez, M. S., Ortega-Álvaro, A., Busquets-García, A., Pérez‐Ortiz, J. M., Caltana, L. R., Ricatti, M. J., Brusco, A., Maldonado, R. J., & Manzanares, J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.034 · Cited by 126
Self-citation
Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice
Steiner, M. A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500466 · Cited by 130
Decreased Cocaine Motor Sensitization and Self-Administration in Mice Overexpressing Cannabinoid CB2 Receptors
Aracil-Fernández, A., Trigo, J. M., García‐Gutiérrez, M. S., Ortega-Álvaro, A., Ternianov, A., Navarro, D., Robledo, P., Berbel, P. J., Maldonado, R. J., & Manzanares, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.22 · Cited by 119
Self-citation
Modulation of the serotonin system by endocannabinoid signaling
Haj‐Dahmane, S., & Shen, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.016 · Cited by 126
Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation
Zoppi, S., Perez‐Nievas, B. G., Madrigal, J. L. M., Manzanares, J., Leza, J. C., & García‐Bueno, B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.214 · Cited by 125
Self-citation
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 120
An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives
Fattore, L., Spano, M. S., Deiana, S., Melis, V., Cossu, G., Fadda, P., & Fratta, W. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.05.003 · Cited by 110
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission
Haller, J., Mátyás, F., Soproni, K., Varga, B., Barsy, B., Németh, B., Mikics, É., Freund, T. F., & Hájos, N. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05476.x · Cited by 103
CB1 receptor deficiency decreases wheel-running activity: Consequences on emotional behaviours and hippocampal neurogenesis
Dubreucq, S., Koehl, M., Abrous, D. N., Marsicano, G., & Chaouloff, F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.01.017 · Cited by 103
The Role of Cannabinoids in Modulating Emotional and Non-Emotional Memory Processes in the Hippocampus
Akirav, I. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00034 · Cited by 102
The Clinical Implications of Mouse Models of Enhanced Anxiety
Sartori, S. B., Landgraf, R., & Singewald, N. (2011) · Future Neurology · doi:10.2217/fnl.11.34 · Cited by 103
Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-na??ve and plus-maze-experienced mice
Rodgers, R. J., Evans, P., & Murphy, A. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00013 · Cited by 101
Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission
Jacob, W., Yassouridis, A., Marsicano, G., Monory, K., Lutz, B., & Wotjak, C. T. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00512.x · Cited by 95
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
The endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 94
The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior
Fogaça, M. V., de Aguiar, D. C., Moreira, F. A., & Guimarães, F. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.007 · Cited by 89
Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
Finn, D. P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.05.011 · Cited by 91
Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice
Naderi, N., Haghparast, A., Saber-Tehrani, A. S., Rezaii, N., Alizadeh, A.-M., Khani, A., & Motamedi, F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.11.001 · Cited by 87
Role of Endocannabinoid Signaling in Anxiety and Depression
Patel, S., & Hillard, C. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_14 · Cited by 91
Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
The Role of the Endocannabinoid System in the Regulation of Hypothalamic‐Pituitary‐Adrenal Axis Activity
Cota, D. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01673.x · Cited by 82
Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning
Tsetsenis, T., Younts, T. J., Chiu, C. Q., Kaeser, P. S., Castillo, P. E., & Südhof, T. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112237108 · Cited by 81
Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice
Fride, E., Suris, R., Weidenfeld, J., & Mechoulam, R. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00016 · Cited by 83
CB1 knockout mice display impaired functionality of 5‐HT1A and 5‐HT2A/C receptors
Mato, S., Aso, E., Castro, E., Martín, M., Valverde, O., Maldonado, R. J., & Pazos, Á. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04961.x · Cited by 80
Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia
Seillier, A., Martinez, A. A., & Giuffrida, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.81 · Cited by 79
The endocannabinoid system in mental disorders: Evidence from human brain studies
Ibarra‐Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, Á., & Callado, L. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.009 · Cited by 84
Self-citation
The endocannabinoid signaling system: Pharmacological and therapeutic aspects
Fowler, C. J., Holt, S., Nilsson, O. R., Jonsson, K., Tiger, G., & Jacobsson, S. O. P. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.023 · Cited by 76
Animal Models of Anxiety and Anxiolytic Drug Action
Treit, D., Engin, E., & McEown, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_17 · Cited by 79
Endocannabinoids: Effectors of glucocorticoid signaling
Balsevich, G., Petrie, G. N., & Hill, M. N. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.07.005 · Cited by 82
Contributions of animal models to the study of mood disorders
Valvassori, S. S., Budni, J., Varela, R. B., & Quevedo, J. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1168 · Cited by 78
Heterozygous neuregulin 1 mice display greater baseline and Δ9-tetrahydrocannabinol-induced c-Fos expression
Boucher, A. A., Hunt, G. E., Karl, T., Micheau, J., McGregor, I. S., & Arnold, J. C. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.08.020 · Cited by 73
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
Mangieri, R. A., & Piomelli, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.003 · Cited by 73
CB1 cannabinoid receptor-mediated aggressive behavior
Rodríguez‐Arias, M., Navarrete, F., Daza‐Losada, M., Navarro, D., Aguilar, M. A., Berbel, P. J., Miñarro, J., & Manzanares, J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.013 · Cited by 72
Self-citation
Modulation of Fear and Anxiety by the Endogenous Cannabinoid System
Chhatwal, J. P., & Ressler, K. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020939 · Cited by 71
Endocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 72
Altered CB1receptor‐signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine
Rodríguez‐Gaztelumendi, A., Rojo, M. L., Pazos, Á., & Díaz, Á. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05898.x · Cited by 68
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 71
Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents
Wade, M. R., Degroot, A., & Nomikos, G. G. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.083 · Cited by 67
Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects
Mendiguren, A., Aostri, E., & Pineda, J. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.029 · Cited by 68
Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors
Umathe, S. N., Manna, S. S. S., Utturwar, K. S., & Jain, N. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.020 · Cited by 69
The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives
Marco, E. M., & Laviola, G. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408459 · Cited by 67
Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims
García‐Gutiérrez, M. S., Navarrete, F., Navarro, G., Reyes‐Resina, I., Franco, R., Lanciego, J. L., Giner, S., & Manzanares, J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0610-y · Cited by 67
Self-citation
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Liu, C. S., Chau, S. A., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2015) · CNS Drugs · doi:10.1007/s40263-015-0270-y · Cited by 63
Long-Term Fluoxetine Treatment Modulates Cannabinoid Type 1 Receptor-Mediated Inhibition of Adenylyl Cyclase in the Rat Prefrontal Cortex through 5-Hydroxytryptamine1A Receptor-Dependent Mechanisms
Mato, S., Vidal, R., Castro, E., Díaz, Á., Pazos, Á., & Valdizán, E. M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060079 · Cited by 63
Analysis of the Endocannabinoid System by Using CB1 Cannabinoid Receptor Knockout Mice
Valverde, O., Karsak, M., & Zimmer, A. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_4 · Cited by 61
The effects of cannabinoids on contextual conditioned fear in CB1 knockout and CD1 mice
Mikics, É., Dombi, T., Barsvári, B., Varga, B., Ledent, C., Freund, T., & Haller, J. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200605000-00003 · Cited by 61
Self-citation
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects
Rahn, E. J., Thakur, G. A., Wood, J. A. T., Zvonok, A. M., Makriyannis, A., & Hohmann, A. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.024 · Cited by 57
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 56
Cannabinoids in depressive disorders
Poleszak, E., Wośko, S., Sławińska, K., Szopa, A., Wróbel, A., & Serefko, A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.058 · Cited by 56
Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic–pituitary–adrenal axis responses in male Sprague–Dawley rats
Newsom, R. J., Osterlund, C., Masini, C. V., Day, H. E., Spencer, R. L., & Campeau, S. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.11.043 · Cited by 54
Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain
Oliva, J. M., Urigüen, L., Pérez-Rial, S., & Manzanares, J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.014 · Cited by 50
Self-citation
Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice
Chegini, H., Nasehi, M., & Zarrindast, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.12.007 · Cited by 52
Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression
Bassi, M. S., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00424 · Cited by 51
Activation of Anxiogenic Circuits Instigates Resistance to Diet-Induced Obesity via Increased Energy Expenditure
(2019) · doi:10.1016/j.cmet.2018.12.018 · Cited by 49
Role of endocannabinoid system in mental diseases
Manzanares, J., Urigüen, L., Rubio, G., & Palomo, T. (2004) · Neurotoxicity Research · doi:10.1007/bf03033223 · Cited by 49
Self-citation
Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice
Austrich-Olivares, A., García‐Gutiérrez, M. S., Illescas, L., Gasparyan, A., & Manzanares, J. (2022) · Pharmaceuticals · doi:10.3390/ph15040473 · Cited by 52
Self-citation
CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement
Touriño, C., Ledent, C. A., Maldonado, R. J., & Valverde, O. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.003 · Cited by 46
Self-citation
Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure
Hill, M. N., & Gorzalka, B. B. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.11.010 · Cited by 49
Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability
Häring, M., Enk, V., Rey, A. A., Loch, S., de Azúa, I. R., Weber, T., Bartsch, D., Monory, K., & Lutz, B. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00235 · Cited by 47
Coexpression of the cannabinoid receptor type 1 with the corticotropin-releasing hormone receptor type 1 in distinct regions of the adult mouse forebrain
Hermann, H., & Lutz, B. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.080 · Cited by 45

Authors: Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J.
Affiliations: Hospital Universitario 12 De Octubre (ES)
Université Libre de Bruxelles (BE)
Corresponding author: Manzanares, Jorge
ORCID: Urigüen, Leyre
Pérez-Rial, Sandra
Ledent, Catherine
Palomo, Tomás
Manzanares, Jorge
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2004-06
Volume: 46
Issue: 7
Pages: 966-973
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2004.01.003
OpenAlex: W2031501939
Cited by: 218
References: 27
Citations by year: 2026: 3 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 16 · 2014: 8 · 2013: 14 · 2012: 9
FWCI: 9.84
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Funders: Eusko Jaurlaritza
National Institutes of Health
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: CB1 receptor, anxiolytics, anxiety-like behavior, bromazepam, buspirone, corticosterone, proopiomelanocortin, pituitary gland, restraint stress, CB1 receptor knockout mice, emotion regulation, anxiety disorders
MeSH terms: Animals, Anxiety, Darkness, Lighting, Male, Motor Activity, Anti-Anxiety Agents, Mice, Knockout, Receptor, Cannabinoid, CB1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks